Additional file 7: Table S4. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Anti-GAB2 IP of Imatinib, Axitinib and Sorafenib vs DMSO treated cells. SILAC ratios are normalized to GAB2. Only sites with localization probabilities greater 0.75 and Andromeda scores greater 40 are shown. PEP: posterior error probability. (XLSX 12 kb)